Publications by authors named "Petra Rotariu"
Article Synopsis
- Castleman disease (CD) is a rare non-cancerous condition that can be unicentric or multicentric (MCD), with MCD leading to serious symptoms due to cytokine issues, particularly involving interleukin-6 (IL-6).
- This study examined the real-world effectiveness of siltuximab, an anti-IL-6 therapy recommended for idiopathic MCD, in treating patients in Greece and Romania from 2017 to 2022.
- Out of 48 patients treated, 71.1% had a response to the treatment, with a 3-year survival rate of 74%, but some patients experienced adverse effects like elevated liver enzymes and anxiety.
J Cell Mol Med
September 2024
Article Synopsis
- * Treatment with hypomethylating agents like azacytidine is common, but patient responses vary, necessitating better understanding through genetic and epigenetic analysis, particularly RNA methylation.
- * Recent research focused on RNA methylation in MDS patients to determine factors that distinguish responders from non-responders to azacytidine, suggesting that analyzing the methylome can provide more accurate prognostic insights for high-grade MDS patients.
